Nevirapine Extended-Release Formulation Tablets in HIV-1–Infected Children—Long-term Follow-up: Table 1. | Zendy

Gabriel Anabwani | Zendy; Christoph Königs | Zendy; Carlo Giaquinto | Zendy; Stella Aslanyan | Zendy; John P. Sabo | Zendy; Jordan Morrow | Zendy; Cornelia FeiternaSperling | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nevirapine Extended-Release Formulation Tablets in HIV-1–Infected Children—Long-term Follow-up: Table 1.

Author(s) -

Gabriel Anabwani,

Christoph Königs,

Carlo Giaquinto,

Stella Aslanyan,

John P. Sabo,

Jordan Morrow,

Cornelia FeiternaSperling

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ340

Subject(s) - nevirapine , medicine , regimen , human immunodeficiency virus (hiv) , clinical trial , viral load , pediatrics , virology , antiretroviral therapy

In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research